Furthermore, disrupting this interaction sensitized ALL cells to chemotherapy, indicating that inhibition of the ANX2/p11 axis has potential therapeutic value to treat ALL, especially when used in combination with existing drugs. This evidence concerns the gene ANXA2 and acute lymphoblastic leukemia.